Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmonx Corp LUNG

Healthcare Medical Devices
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX... see more

Recent & Breaking News (NDAQ:LUNG)

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 6, 2024

Pulmonx Reports First Quarter 2024 Financial Results

GlobeNewswire May 1, 2024

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024

GlobeNewswire April 10, 2024

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

GlobeNewswire April 2, 2024

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 15, 2024

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

Business Wire February 26, 2024

Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 21, 2024

Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

GlobeNewswire February 21, 2024

Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024

GlobeNewswire February 7, 2024

The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

GlobeNewswire December 11, 2023

Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire November 15, 2023

Pulmonx to Participate at Upcoming Investor Conferences

GlobeNewswire October 31, 2023

Pulmonx Reports Record Third Quarter 2023 Financial Results

GlobeNewswire October 30, 2023

Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023

GlobeNewswire October 16, 2023

Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue

GlobeNewswire October 10, 2023

Pulmonx to Participate at Upcoming Investor Conferences

GlobeNewswire August 30, 2023

Pulmonx Reports Second Quarter 2023 Financial Results

GlobeNewswire August 2, 2023

Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference

GlobeNewswire July 26, 2023

Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023

GlobeNewswire July 17, 2023

Pulmonx Reports First Quarter 2023 Financial Results

GlobeNewswire May 2, 2023